{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T17:57:38Z","timestamp":1778176658628,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00198-019-04997-6","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T04:55:46Z","timestamp":1556686546000},"page":"1723-1732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials"],"prefix":"10.1007","volume":"30","author":[{"given":"W.-C.","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.-Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8244-2846","authenticated-orcid":false,"given":"Y.-N.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"key":"4997_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785\u2013795","journal-title":"JAMA"},{"key":"4997_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s00774-014-0603-9","volume":"33","author":"M Hongo","year":"2015","unstructured":"Hongo M, Miyakoshi N, Kasukawa Y, Ishikawa Y, Shimada Y (2015) Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial. J Bone Miner Metab 33:432\u2013439","journal-title":"J Bone Miner Metab"},{"key":"4997_CR3","doi-asserted-by":"crossref","unstructured":"Tanaka S, Yoshida A, Kono S, Oguma T, Hasegawa K, Ito M (2016) Effectiveness of elcatonin for alleviating pain and inhibiting bone resorption in patients with osteoporotic vertebral fractures. J Bone Miner Metab","DOI":"10.1007\/s00774-016-0791-6"},{"key":"4997_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N (2005) Assessment of fracture risk. Osteoporos Int 16:581\u2013589","journal-title":"Osteoporos Int"},{"key":"4997_CR5","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/ije\/dyp276","volume":"39","author":"N Yoshimura","year":"2010","unstructured":"Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T (2010) Cohort profile: Research on Osteoarthritis\/Osteoporosis Against Disability study. Int J Epidemiol 39:988\u2013995","journal-title":"Int J Epidemiol"},{"key":"4997_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/BF01927568","volume":"32","author":"T Morikawa","year":"1976","unstructured":"Morikawa T, Munekata E, Sakakibara S, Noda T, Otani M (1976) Synthesis of eel-calcitonin and (asu1,7)-eel-calcitonin: contribution of the disulfide bond to the hormonal activity. Experientia 32:1104\u20131106","journal-title":"Experientia"},{"key":"4997_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF02491385","volume":"15","author":"T Fujita","year":"1997","unstructured":"Fujita T, Fujii Y, Goto B, Miyauchi A, Takagi Y (1997) A three-year comparative trial in osteoporosis treatment: effect of combined alfacalcidol and elcatonin. J Bone Miner Metab 15:223\u2013226","journal-title":"J Bone Miner Metab"},{"key":"4997_CR8","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00198-004-1798-8","volume":"16","author":"JA Knopp","year":"2005","unstructured":"Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH (2005) Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 16:1281\u20131290","journal-title":"Osteoporos Int"},{"key":"4997_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00774-004-0556-5","volume":"23","author":"K Yoh","year":"2005","unstructured":"Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y, Tobinaga M, Hasegawa N, Kamae S, Yoshizawa M (2005) Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment. J Bone Miner Metab 23:167\u2013173","journal-title":"J Bone Miner Metab"},{"key":"4997_CR10","first-page":"2011","volume":"4","author":"JJ Barendregt","year":"2016","unstructured":"Barendregt JJ, Doi SA (2016) MetaXL user guide. Version 4:2011\u20132016","journal-title":"Version"},{"key":"4997_CR11","doi-asserted-by":"crossref","unstructured":"Higgins JP, Green S (2008) Cochrane handbook for systematic reviews of interventions","DOI":"10.1002\/9780470712184"},{"key":"4997_CR12","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0011-393X(05)80760-X","volume":"55","author":"F Astengo","year":"1994","unstructured":"Astengo F, Della Monica A, Fontana L, Fuliano P, Bigolari M (1994) Efficacy and safety of two elcatonin regimens in the treatment of osteoporosis. Curr Ther Res Clin Exp 55:1518\u20131526","journal-title":"Curr Ther Res Clin Exp"},{"key":"4997_CR13","first-page":"369","volume":"50","author":"V Consoli","year":"1991","unstructured":"Consoli V, Alfieri P, Giuntini C, Manca M, Avaldi F, Soncini R (1991) A double-blind placebo-controlled trial of the efficacy and tolerability of intranasal elcatonin administered to patients suffering from senile and postmenopausal osteoporosis. Curr Ther Res Clin Exp 50:369\u2013378","journal-title":"Curr Ther Res Clin Exp"},{"key":"4997_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00774-016-0765-8","volume":"35","author":"N Endo","year":"2017","unstructured":"Endo N, Fujino K, Doi T, Akai M, Hoshino Y, Nakano T, Iwaya T (2017) Effect of elcatonin versus nonsteroidal anti-inflammatory medications for acute back pain in patients with osteoporotic vertebral fracture: a multiclinic randomized controlled trial. J Bone Miner Metab 35:375\u2013384","journal-title":"J Bone Miner Metab"},{"key":"4997_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s007740050097","volume":"17","author":"T Fujita","year":"1999","unstructured":"Fujita T, Fujii Y, Miyauchi A, Takagi Y (1999) Comparison of antiresorptive activities of ipriflavone, an isoflavone derivative, and elcatonin, an eel carbocalcitonin. J Bone Miner Metab 17:289\u2013295","journal-title":"J Bone Miner Metab"},{"key":"4997_CR16","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00198-010-1495-8","volume":"22","author":"J Iwamoto","year":"2011","unstructured":"Iwamoto J, Makita K, Sato Y, Takeda T, Matsumoto H (2011) Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. Osteoporos Int 22:2735\u20132742","journal-title":"Osteoporos Int"},{"key":"4997_CR17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3760\/cma.j.issn.0366-6999.20121626","volume":"126","author":"Y Li","year":"2013","unstructured":"Li Y, Xuan M, Wang B et al (2013) Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China. Chin Med J 126:457\u2013463","journal-title":"Chin Med J"},{"key":"4997_CR18","first-page":"79","volume":"17","author":"R Lobianco","year":"1992","unstructured":"Lobianco R, Merola B, Lupoli G, Cocca A, Guarino M, Pia M, Guerriero S, Lombardi G (1992) Randomized comparative study using carbocalcitonin i.m. vs carbocalcitonin nasal spray vs ipriflavone x os in the treatment of post-menopausal osteoporosis. Minerva Endocrinol 17:79\u201384","journal-title":"Minerva Endocrinol"},{"key":"4997_CR19","first-page":"399","volume":"17","author":"C Lozano-Tonkin","year":"2000","unstructured":"Lozano-Tonkin C, Gracia Canales A, Jare\u00f1o J, Mercadal J (2000) Long-term double-blind study of the efficacy of intermitent nasal elcatonin in recent postmenopausal women. An Med Interna 17:399\u2013405","journal-title":"An Med Interna"},{"key":"4997_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0028-2243(92)90214-J","volume":"47","author":"M Meschia","year":"1992","unstructured":"Meschia M, Brincat M, Barbacini P, Carena Maini M, Marri R, Crosignani PG (1992) Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 47:53\u201357","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"4997_CR21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0378-5122(96)00999-1","volume":"23","author":"MD P\u00e9rez-Jaraiz","year":"1996","unstructured":"P\u00e9rez-Jaraiz MD, Revilla M, Alvarez De Los Heros JI, Villa LF, Rico H (1996) Prophylaxis of osteoporosis with calcium, estrogens and\/or eelcatonin: comparative longitudinal study of bone mass. Maturitas 23:327\u2013332","journal-title":"Maturitas"},{"key":"4997_CR22","unstructured":"Sugimoto T, Shiraki M, Nakano T, et al (2018) A randomized, double-blind, placebo-controlled study of once weekly elcatonin in primary postmenopausal osteoporosis. Curr Med Res Opin 1\u20138"},{"key":"4997_CR23","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jos.2016.12.021","volume":"22","author":"S Tanaka","year":"2017","unstructured":"Tanaka S, Yoshida A, Kono S, Ito M (2017) Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment in patients with new vertebral fractures: an open-label, randomized, parallel-group study. J Orthop Sci 22:536\u2013541","journal-title":"J Orthop Sci"},{"key":"4997_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S1995-7645(14)60192-9","volume":"8","author":"Y Yang","year":"2015","unstructured":"Yang Y, Zhang X-J, Zhu X-J, Zhang L, Bao M-J, Xian Y, Wu J-C, Liu L-M, Li P-Q (2015) Comparison between recombinant human parathyroid hormone (1\u201334) and elcatonin in treatment of primary osteoporosis. Asian Pac J Trop Med 8:79\u201384","journal-title":"Asian Pac J Trop Med"},{"key":"4997_CR25","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00198-012-1956-3","volume":"24","author":"L Zhang","year":"2013","unstructured":"Zhang L, Li L, Yang M, Xu K, Boden G, Yang G (2013) The rhPTH treatment elevates plasma secreted protein acidic and rich in cysteine levels in patients with osteoporosis. Osteoporos Int 24:1107\u20131112","journal-title":"Osteoporos Int"},{"key":"4997_CR26","first-page":"662","volume":"49","author":"XZ Zhang","year":"2010","unstructured":"Zhang XZ, Song LG, Wang B et al (2010) A randomized, multicenter, active-controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with that of elcatonin in postmenopausal women with osteoporosis in China. Zhonghua Nei Ke Za Zhi 49:662\u2013666","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"4997_CR27","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1097\/00029330-200901020-00015","volume":"122","author":"XZ Zhang","year":"2009","unstructured":"Zhang XZ, Wang B, Yang J et al (2009) A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China. Chin Med J 122:2933\u20132938","journal-title":"Chin Med J"},{"key":"4997_CR28","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1359\/jbmr.070505","volume":"22","author":"KK Ivaska","year":"2007","unstructured":"Ivaska KK, Gerdhem P, Akesson K, Garnero P, Obrant KJ (2007) Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res Off J Am Soc Bone Miner Res 22:1155\u20131164","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"4997_CR29","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s001980200118","volume":"13","author":"SL Silverman","year":"2002","unstructured":"Silverman SL, Azria M (2002) The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 13:858\u2013867","journal-title":"Osteoporos Int"},{"key":"4997_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0091-3057(98)00015-X","volume":"60","author":"K Shibata","year":"1998","unstructured":"Shibata K, Takeda M, Ito A, Takeda M, Sagai H (1998) Ovariectomy-induced hyperalgesia and antinociceptive effect of elcatonin, a synthetic eel calcitonin. Pharmacol Biochem Behav 60:371\u2013376","journal-title":"Pharmacol Biochem Behav"},{"key":"4997_CR31","unstructured":"Committee TEMAs (2012) European Medicines Agency recommends limiting longterm use of calcitonin medicines. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2012\/07\/WC500130122.pdf . Accessed 29 Aug 2018"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-04997-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-04997-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-04997-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T14:07:48Z","timestamp":1721225268000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-04997-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4997"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-04997-6","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]},"assertion":[{"value":"20 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}